Business Summary
|
RegeneRx Biopharmaceuticals, Inc. (RegeneRx) is a biopharmaceutical company focused on the discovery and development of molecules to promote tissue and organ protection, repair and regeneration. As of December 31, 2009, the Company had formulated three product candidates based on Thymosin beta 4 (Tb4), a 43-amino acid peptide, which are in clinical development. RGN-137 is a topically applied for chronic dermal wounds and reduction of scar tissue. RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic indications. RGN-352, a parenteral or injectable formulation for systemic delivery to treat cardiovascular diseases, central nervous system diseases, and other medical indications that require administration by injection. The Company is initially targeting RGN-352 for the treatment of patients who have suffered an acute myocardial infarction (AMI) or heart attack.
| | (Source: 10-K)
|
|
|
